EA201001589A1 - Immobilized erythropoietin - Google Patents
Immobilized erythropoietinInfo
- Publication number
- EA201001589A1 EA201001589A1 EA201001589A EA201001589A EA201001589A1 EA 201001589 A1 EA201001589 A1 EA 201001589A1 EA 201001589 A EA201001589 A EA 201001589A EA 201001589 A EA201001589 A EA 201001589A EA 201001589 A1 EA201001589 A1 EA 201001589A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- erythropoietin
- treatment
- encapsulated
- immobilized
- polymer
- Prior art date
Links
Abstract
Предложен эритропоэтин (ЭПО), представляющий собой рекомбинантный человеческий или модифицированный эритропоэтин альфа, или его аналог, инкапсулированный в наночастицы и/или микрочастицы из фармацевтически пригодных, биосовместимых и биодеградируемых (со)полимер(ов) и/или полимерных матриц, и/или сорбированный и/или адсорбированный на их поверхности, и/или инкапсулированный в липосомы. Новая форма эритропоэтина может быть использована для создания лекарственных препаратов для лечения и/или профилактики неврологических и гематологических заболеваний и нарушений, а также для лечения нарушений зрения, ретинопатии при недоношенности и др.Erythropoietin (EPO), which is a recombinant human or modified erythropoietin alpha, or its analog encapsulated in nanoparticles and / or microparticles from pharmaceutically acceptable, biocompatible and biodegradable (co) polymer (s) and / or polymer matrices, and / or sorbated and / or adsorbed on their surface, and / or encapsulated in liposomes. A new form of erythropoietin can be used to create drugs for the treatment and / or prevention of neurological and hematological diseases and disorders, as well as for the treatment of visual impairment, retinopathy with prematurity, etc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201001589A EA018472B1 (en) | 2010-09-15 | 2010-09-15 | Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201001589A EA018472B1 (en) | 2010-09-15 | 2010-09-15 | Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201001589A1 true EA201001589A1 (en) | 2012-02-28 |
EA018472B1 EA018472B1 (en) | 2013-08-30 |
Family
ID=45908217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201001589A EA018472B1 (en) | 2010-09-15 | 2010-09-15 | Erythropoietin-containing particles for treatment and prophylaxis of neurologic and hematologic diseases and disorders |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA018472B1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035845A1 (en) * | 1992-06-11 | 2003-02-20 | Zale Stephen E. | Composition for sustained release of non-aggregated erythropoietin |
WO1999038536A1 (en) * | 1998-01-29 | 1999-08-05 | Poly-Med Inc. | Absorbable microparticles |
DK0937456T3 (en) * | 1998-02-23 | 2004-11-08 | Cilag Ag Int | Liposomal dispersion of erythropoietin |
RU2271196C2 (en) * | 1999-06-04 | 2006-03-10 | Элзэ Копэрейшн | Implantable composition (variants) and method for production thereof |
US7879361B2 (en) * | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
CN101507712B (en) * | 2009-03-20 | 2011-08-17 | 河北师范大学 | Sustained-release micro-spheres preparation containing recombined erythropoietin |
-
2010
- 2010-09-15 EA EA201001589A patent/EA018472B1/en active IP Right Revival
Also Published As
Publication number | Publication date |
---|---|
EA018472B1 (en) | 2013-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3300728A3 (en) | Treatment of circadian rhythm disorders | |
BR112013003677A2 (en) | use of pharmacologically active agent and pharmaceutical dosage form | |
EA201300669A1 (en) | SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION | |
PH12015500407A1 (en) | Methods of treating hypertriglyceridemia | |
EP3050876A3 (en) | Kinase modulators | |
UA108198C2 (en) | Substituted 2-acetamido-5-aryl-l, 2,4-triazolones and their use | |
BR112013015859A2 (en) | compound, use of a compound, methods of prevention, treatment, amelioration or prophylaxis of physiological disorders or diseases, and treatment or amelioration of cosmetic indications, and, pharmaceutical composition | |
WO2013184876A8 (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
WO2009111317A3 (en) | Endoscopic delivery of red/nir light to the substantia nigra to treat parkinson's disease | |
MX2015002289A (en) | Human antibodies to gfrî±3 and methods of use thereof. | |
EP2268140A4 (en) | Novel compounds advantageous in the treatment of central nervous system diseases and disorders | |
IN2014DN06710A (en) | ||
MX2019000547A (en) | Stabilized liquid and lyophilized adamts13 formulations. | |
CL2012001673A1 (en) | Substituted benzamide derivative compounds, as modulators of taar; preparation procedure; pharmaceutical composition; and its use in the treatment of depression, anxiety disorders, bipolar disorder, schizophrenia, epilepsy, migraine, Alzheimer's disease, metabolic disorders, among others. | |
MX2014008842A (en) | Dental implant and method for producing a dental implant. | |
MX2012004078A (en) | Compounds and compositions as modulators of gpr119 activity. | |
GB2496800B (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
BR112012030331A2 (en) | neuregulin isoforms, neuregulin polypeptides, and uses thereof | |
EA201171283A1 (en) | NEW TECHNOLOGY OF MELOXICAM MANUFACTURE | |
EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
WO2014106116A3 (en) | Therapeutic compositions comprising antibodies | |
BR112014011744A2 (en) | sustainable action formulation of cyclosporine form 2 | |
EA201492102A1 (en) | ANTAGONISTS LINGO-2 FOR THE TREATMENT OF DISEASES IN WHICH MOTOR NEURONS PARTICIPATE | |
IN2014KN02687A (en) | ||
EA201690005A1 (en) | COMPOSITION WITH MODIFIED EXTRUSION KINETICS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY KZ RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AZ BY KZ RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AM KG MD TJ TM |
|
TC4A | Change in name of a patent proprietor in a eurasian patent | ||
PC4A | Registration of transfer of a eurasian patent by assignment |